Physical Exercise as a Sustainability Tool in Men With Dysmetabolic Hypogonadism
ExLOH
1 other identifier
interventional
72
1 country
1
Brief Summary
Aim of this project is to delineate sustainable physical exercise programs and to assess the effects of such programs mainly on endocrine-metabolic and neurovegetative outcomes in a cohort of men with metabolic syndrome-related late-onset central hypogonadism. Participants will undergo a personalised exercise program. After 6 months they will be subdivided into two groups, according to the weekly physical activity volume actually performed (above or below 600 MET·minutes/week). Changes in endocrine-metabolic and neurovegetative outcomes will be compared between the two groups.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jan 2023
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 11, 2023
CompletedFirst Submitted
Initial submission to the registry
October 6, 2023
CompletedFirst Posted
Study publicly available on registry
October 23, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2024
CompletedMarch 12, 2024
March 1, 2024
1.9 years
October 6, 2023
March 8, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
change in hypothalamic-pituitary-gonadal axis function
particularly testosterone levels (nmol/l)
6 months
Secondary Outcomes (16)
Change in body composition
6 months
Change in serum skeletal isoenzyme of alkaline phosphatase
6 months
Change in C-terminal telopeptide of type I collagen
6 months
Change in erythrocyte sedimentation rate
6 months
Change in C-reactive protein
6 months
- +11 more secondary outcomes
Study Arms (2)
weekly physical activity volume performed above 600 MET·minutes/week
OTHERExercise program requiring clear definition of modality, intensity, frequency, duration and progression of exercise, tailored on patient's clinical conditions and goals.
weekly physical activity volume performed below 600 MET·minutes/week
OTHERExercise program requiring clear definition of modality, intensity, frequency, duration and progression of exercise, tailored on patient's clinical conditions and goals.
Interventions
In line with the most recent guidelines, exercise prescription will require the clear definition of modality, intensity, frequency, duration and progression of exercise, tailored on patient's clinical conditions and goals. This intervention will be accompanied by a nutrition program aiming for proper dietary habits in terms of both quantity and quality.
Eligibility Criteria
You may qualify if:
- diagnosis of late-onset central hypogonadism: total T levels \< 8 nmol/L (or \< 12 nmol/L in the presence of calculated free T \< 225 pmol/L) combined with sexual symptoms (erectile dysfunction, low libido and loss of waking erections) \[12\];
- diagnosis of metabolic syndrome, defined as association of waist circumference (WC) \> 94 cm and at least two among the following criteria: triglycerides ≥ 150 mg/dl, HDL-C \< 40 mg/dl, glucose \> 100 mg/dl, blood pressure (BP) ≥ 130/85 mmHg \[33\];
- ability to give informed consent, in accordance with good clinical practice rules and applicable national laws.
You may not qualify if:
- History of hypothalamus-pituitary organic disorders and/or testicular diseases;
- impossibility to assess cardiac autonomic regulation due to arrhythmias and/or current treatment for heart rate (HR) control (e.g., beta-blockers, antiarrhythmics);
- impossibility to undergo clinical assessment;
- impossibility or contraindications to perform exercise program (for instance, psychiatric disorders, severe musculoskeletal diseases, arrhythmias);
- inability to give informed consent or unwillingness to be enrolled in the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Istituto Auxologico Italiano IRCCS
Milan, Italy
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Daniela Lucini, MD, PhD
University of Milan; Istituto Auxologico Italiano, IRCCS
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 6, 2023
First Posted
October 23, 2023
Study Start
January 11, 2023
Primary Completion
December 1, 2024
Study Completion
December 31, 2024
Last Updated
March 12, 2024
Record last verified: 2024-03